Suppr超能文献

豇豆花叶病毒粒子的效力对原位癌症疫苗接种没有影响,具体包被的病毒 RNA 也是如此。

The Potency of Cowpea Mosaic Virus Particles for Cancer In Situ Vaccination Is Unaffected by the Specific Encapsidated Viral RNA.

机构信息

Department of Nanoengineering, University of California San Diego, La Jolla, California 92093, United States.

Department of Bioengineering, University of California San Diego, La Jolla, California 92093, United States.

出版信息

Mol Pharm. 2023 Jul 3;20(7):3589-3597. doi: 10.1021/acs.molpharmaceut.3c00214. Epub 2023 Jun 9.

Abstract

Plant virus nanoparticles can be used as drug carriers, imaging reagents, vaccine carriers, and immune adjuvants in the formulation of intratumoral in situ cancer vaccines. One example is the cowpea mosaic virus (CPMV), a nonenveloped virus with a bipartite positive-strand RNA genome with each RNA packaged separately into identical protein capsids. Based on differences in their densities, the components carrying RNA-1 (6 kb) denoted as the bottom (B) component or carrying RNA-2 (3.5 kb) denoted as the middle (M) component can be separated from each other and from a top (T) component, which is devoid of any RNA. Previous preclinical mouse studies and canine cancer trials used mixed populations of CPMV (containing B, M, and T components), so it is unclear whether the particle types differ in their efficacies. It is known that the CPMV RNA genome contributes to immunostimulation by activation of TLR7. To determine whether the two RNA genomes that have different sizes and unrelated sequences cause different immune stimulation, we compared the therapeutic efficacies of B and M components and unfractionated CPMV in vitro and in mouse cancer models. We found that separated B and M particles behaved similarly to the mixed CPMV, activating innate immune cells to induce the secretion of pro-inflammatory cytokines such as IFNα, IFNγ, IL-6, and IL-12, while inhibiting immunosuppressive cytokines such as TGF-β and IL-10. In murine models of melanoma and colon cancer, the mixed and separated CPMV particles all significantly reduced tumor growth and prolonged survival with no significant difference. This shows that the specific RNA genomes similarly stimulate the immune system even though B particles have 40% more RNA than M particles; each CPMV particle type can be used as an effective adjuvant against cancer with the same efficacy as native mixed CPMV. From a translational point of view, the use of either B or M component vs the mixed CPMV formulation offers the advantage that separated B or M alone is noninfectious toward plants and thus provides agronomic safety.

摘要

植物病毒纳米颗粒可用作药物载体、成像试剂、疫苗载体和免疫佐剂,用于构建肿瘤内原位癌症疫苗。例如,豇豆花叶病毒(CPMV)是一种无包膜的病毒,具有分段的正链 RNA 基因组,每个 RNA 分别包装在相同的蛋白衣壳中。根据其密度的差异,可以将携带 RNA-1(6kb)的成分(表示为底部(B)成分)或携带 RNA-2(3.5kb)的成分(表示为中间(M)成分)彼此以及与顶部(T)成分分离,T 成分不含任何 RNA。以前的临床前小鼠研究和犬科癌症试验使用 CPMV 的混合群体(包含 B、M 和 T 成分),因此尚不清楚粒子类型在功效上是否存在差异。已知 CPMV RNA 基因组通过激活 TLR7 来促进免疫刺激。为了确定大小不同且序列无关的两种 RNA 基因组是否引起不同的免疫刺激,我们比较了 B 和 M 成分以及未分离的 CPMV 在体外和小鼠癌症模型中的治疗功效。我们发现,分离的 B 和 M 颗粒的行为与混合的 CPMV 相似,激活先天免疫细胞诱导促炎细胞因子如 IFNα、IFNγ、IL-6 和 IL-12 的分泌,同时抑制免疫抑制细胞因子如 TGF-β和 IL-10。在黑色素瘤和结肠癌的小鼠模型中,混合和分离的 CPMV 颗粒均显著降低肿瘤生长并延长存活期,无显著差异。这表明,即使 B 颗粒比 M 颗粒多 40%的 RNA,特定的 RNA 基因组也能相似地刺激免疫系统;每种 CPMV 颗粒类型都可以用作有效的癌症佐剂,与天然混合 CPMV 具有相同的功效。从转化的角度来看,与使用混合 CPMV 制剂相比,使用 B 或 M 成分具有单独的 B 或 M 是非感染植物的优势,因此提供了农业安全。

相似文献

1
The Potency of Cowpea Mosaic Virus Particles for Cancer In Situ Vaccination Is Unaffected by the Specific Encapsidated Viral RNA.
Mol Pharm. 2023 Jul 3;20(7):3589-3597. doi: 10.1021/acs.molpharmaceut.3c00214. Epub 2023 Jun 9.
2
Cowpea Mosaic Virus Outperforms Other Members of the Secoviridae as In Situ Vaccine for Cancer Immunotherapy.
Mol Pharm. 2022 May 2;19(5):1573-1585. doi: 10.1021/acs.molpharmaceut.2c00058. Epub 2022 Mar 25.
3
In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma.
Mol Pharm. 2018 Sep 4;15(9):3700-3716. doi: 10.1021/acs.molpharmaceut.8b00316. Epub 2018 May 25.
4
Inactivated Cowpea Mosaic Virus for In Situ Vaccination: Differential Efficacy of Formalin vs UV-Inactivated Formulations.
Mol Pharm. 2023 Jan 2;20(1):500-507. doi: 10.1021/acs.molpharmaceut.2c00744. Epub 2022 Nov 18.
5
Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model.
Mol Pharm. 2022 Feb 7;19(2):592-601. doi: 10.1021/acs.molpharmaceut.1c00681. Epub 2022 Jan 3.
7
In Vivo Fate of Cowpea Mosaic Virus In Situ Vaccine: Biodistribution and Clearance.
ACS Nano. 2022 Nov 22;16(11):18315-18328. doi: 10.1021/acsnano.2c06143. Epub 2022 Oct 20.
8
The unique potency of Cowpea mosaic virus (CPMV) cancer vaccine.
Biomater Sci. 2020 Sep 30;8(19):5489-5503. doi: 10.1039/d0bm01219j.
9
Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy.
Int J Mol Sci. 2021 Sep 8;22(18):9733. doi: 10.3390/ijms22189733.
10
Antibody Response against Cowpea Mosaic Viral Nanoparticles Improves Vaccine Efficacy in Ovarian Cancer.
ACS Nano. 2020 Mar 24;14(3):2994-3003. doi: 10.1021/acsnano.9b07865. Epub 2020 Mar 5.

引用本文的文献

2
Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.
Bioengineering (Basel). 2024 Dec 25;12(1):7. doi: 10.3390/bioengineering12010007.
3
Plant Virus Nanoparticles Combat Cancer.
Vaccines (Basel). 2023 Jul 25;11(8):1278. doi: 10.3390/vaccines11081278.

本文引用的文献

2
Inactivated Cowpea Mosaic Virus for In Situ Vaccination: Differential Efficacy of Formalin vs UV-Inactivated Formulations.
Mol Pharm. 2023 Jan 2;20(1):500-507. doi: 10.1021/acs.molpharmaceut.2c00744. Epub 2022 Nov 18.
3
Virus-like particle vaccinology, from bench to bedside.
Cell Mol Immunol. 2022 Sep;19(9):993-1011. doi: 10.1038/s41423-022-00897-8. Epub 2022 Aug 12.
4
Cowpea Mosaic Virus and Natural Killer Cell Agonism for In Situ Cancer Vaccination.
Nano Lett. 2022 Jul 13;22(13):5348-5356. doi: 10.1021/acs.nanolett.2c01328. Epub 2022 Jun 17.
6
S100A9-Targeted Cowpea Mosaic Virus as a Prophylactic and Therapeutic Immunotherapy against Metastatic Breast Cancer and Melanoma.
Adv Sci (Weinh). 2021 Nov;8(21):e2101796. doi: 10.1002/advs.202101796. Epub 2021 Sep 14.
7
vaccine application of inactivated CPMV nanoparticles for cancer immunotherapy.
Mater Adv. 2021 Mar 7;2(5):1644-1656. doi: 10.1039/D0MA00752H. Epub 2021 Feb 3.
8
Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors.
Biomaterials. 2021 Aug;275:120914. doi: 10.1016/j.biomaterials.2021.120914. Epub 2021 May 25.
9
Cowpea Mosaic Virus Promotes Anti-Tumor Activity and Immune Memory in a Mouse Ovarian Tumor Model.
Adv Ther (Weinh). 2019 May;2(5). doi: 10.1002/adtp.201900003. Epub 2019 Feb 25.
10
Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment.
Immunotherapy. 2021 Jun;13(8):653-659. doi: 10.2217/imt-2020-0332. Epub 2021 Apr 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验